Dermatomyositis and polymyositis (myositis): vizsgálatok itt: Hollandia
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1. fázisTaking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Groningen, Utrecht
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - 3. fázisNot yet taking people in HollandiaA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Amsterdam
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- Amsterdam, Utrecht
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - 1. fázisNot yet taking people in HollandiaA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Amsterdam, Leiden
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-504022-19-01 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Amsterdam
- Életkor
- 18 év to 75 év
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - 1. fázisTaking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Groningen, Utrecht
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - 1. fázisCsak meghívásosPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Groningen, Utrecht
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - 2. fázisTaking peopleFibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 60
- Run by
- Amsterdam UMC Stichting
See details and how to join2025-522834-30-01 - 2. fázisTaking peopleDrug Rediscovery for Rare Immune Mediated Inflammatory Diseases
- Where
- Amsterdam, Heerlen, Nijmegen, Rotterdam, The Hague, Utrecht
- Életkor
- 18 év to 65 év
- People
- 60
- Run by
- UMC Utrecht
See details and how to joinNCT06285539